# TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD

> **NCT04671355** · PHASE4 · WITHDRAWN · sponsor: **Chiesi Farmaceutici S.p.A.**

## Conditions studied

- COPD

## Interventions

- **DRUG:** Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg
- **DRUG:** Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg

## Key facts

- **NCT ID:** NCT04671355
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10-04
- **Primary completion:** 2021-12-22
- **Final completion:** 2022-02-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Continuing delays due to COVID-19 pandemic
- **Last updated:** 2022-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04671355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04671355, "TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04671355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*